Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome

By |2017-01-14T18:08:33-05:00January 14th, 2017|Categories: DSF Research Review|Tags: , , , , |

(Griffin, et. al 2017). Building on previous drug screening in a Dravet syndrome model of zebrafish that identified clemizole, a histamine (H1) receptor antagonist, as having anti-epileptic properties, this study sought to further examine the mechanisms of clemizole's action and expand the class of serotonin-acting compounds to include, among others, the FDA-approved drugs lorcaserin (Belviq) and [...]